High Insulin Levels Genetically Linked to Lower Lipoprotein(a)
By Lori Solomon HealthDay Reporter
WEDNESDAY, Sept. 4, 2024 -- There is an association between genetically predicted increased insulin concentrations and decreased concentrations of circulating lipoprotein(a) (Lp[a]), according to a study published online Aug. 29 in Cardiovascular Diabetology to coincide with the European Society of Cardiology Congress 2024, held from Aug. 30 to Sept. 2 in London.
Mateusz Lejawa, from the University of Silesia in Katowice, Poland, and colleagues examined the relationship between genetically predicted insulin concentrations and Lp(a) levels. The analysis included genetic variants strongly associated with fasting insulin levels from meta-analyses of genome-wide association studies in European populations (151,013 individuals) and summary-level data for Lp(a) from 361,194 participants in the U.K. Biobank.
The researchers found that genetically predicted fasting insulin levels were negatively associated with Lp(a) levels (β = −0.15). A sensitivity analysis supported a causal relationship between genetically predisposed insulin levels and Lp(a) using the weighted median method (β = −0.26), but not the Mendelian randomization-Egger method (β = −0.22).
"These findings suggest that hyperinsulinemia, which typically accompanies type 2 diabetes, can partially explain the inverse relationship between low Lp(a) concentrations and an increased risk of type 2 diabetes," the authors write. "Further studies are needed to validate and establish the exact mechanism behind this relationship."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.